| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1051090491 |
| P356 | DOI | 10.1186/1471-2415-13-39 |
| P932 | PMC publication ID | 3750406 |
| P698 | PubMed publication ID | 23914773 |
| P5875 | ResearchGate publication ID | 255692070 |
| P50 | author | Simon R. Taylor | Q42590171 |
| P2093 | author name string | Andrew D Dick | |
| Lavnish Joshi | |||
| Shenzhen Tempest-Roe | |||
| P2860 | cites work | Infliximab for chronic cystoid macular edema associated with uveitis | Q80871601 |
| Iluvien: a new sustained delivery technology for posterior eye disease | Q81891397 | ||
| intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group | Q82567912 | ||
| Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study | Q83321961 | ||
| Intravitreal methotrexate in uveitis | Q83799506 | ||
| Intravitreal ketorolac for chronic uveitis and macular edema: a pilot study | Q83853998 | ||
| Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective | Q84929331 | ||
| Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema | Q85057723 | ||
| Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema | Q95386125 | ||
| Interleukin 6 induces the expression of vascular endothelial growth factor | Q24316308 | ||
| Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop | Q24727581 | ||
| The danger model: a renewed sense of self | Q28214633 | ||
| Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats | Q28565470 | ||
| Ranibizumab for neovascular age-related macular degeneration | Q29617549 | ||
| Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. | Q30717126 | ||
| Intravitreal dexamethasone effectively reduces postoperative inflammation after vitreoretinal surgery | Q31142616 | ||
| Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation | Q31913255 | ||
| Orbital floor triamcinolone acetonide injections for the management of active non-infectious uveitis | Q33332567 | ||
| Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema | Q79826333 | ||
| Intravitreal bevacizumab for treatment of uveitic macular edema | Q79960243 | ||
| Safety profile of intravitreal triamcinolone acetonide | Q80530355 | ||
| Comparison of orbital floor triamcinolone acetonide and oral prednisolone for cataract surgery management in patients with non-infectious uveitis | Q33524839 | ||
| Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert | Q33536900 | ||
| What is new HLA-B27 acute anterior uveitis? | Q34172654 | ||
| Ocular neuroprotection by siRNA targeting caspase-2 | Q34192944 | ||
| Road to fulfilment: taming the immune response to restore vision | Q34259510 | ||
| From beach to bedside: history of the development of sirolimus | Q34395669 | ||
| Developments in the treatment of uveitis | Q34481964 | ||
| Ranibizumab versus verteporfin for neovascular age-related macular degeneration. | Q34652928 | ||
| Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis | Q34686335 | ||
| Long-term, multicenter evaluation of subconjunctival injection of triamcinolone for non-necrotizing, noninfectious anterior scleritis | Q35250540 | ||
| Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial | Q35319079 | ||
| Interplay between innate and adaptive immunity in the development of non-infectious uveitis | Q35784059 | ||
| A review of evidence guiding the use of corticosteroids in the treatment of intraocular inflammation | Q35895945 | ||
| The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. | Q36441711 | ||
| Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study | Q36722548 | ||
| Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation | Q36786463 | ||
| Advances in the diagnosis and immunotherapy for ocular inflammatory disease | Q37102197 | ||
| International Uveitis Study Group (IUSG): clinical classification of uveitis | Q37124620 | ||
| P2X7 deficiency attenuates renal injury in experimental glomerulonephritis | Q37211139 | ||
| Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology | Q37259057 | ||
| Penetration of topical and subconjunctival corticosteroids into human aqueous humour and its therapeutic significance. | Q37416854 | ||
| More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial | Q37487110 | ||
| The use of intraocular corticosteroids | Q37598893 | ||
| The NLRP3 inflammasome: a sensor for metabolic danger? | Q37675505 | ||
| Nonsteroidal anti-inflammatory drugs in ophthalmology | Q37693301 | ||
| New developments in corticosteroid therapy for uveitis | Q37780430 | ||
| Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response | Q37811988 | ||
| Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behçet uveitis | Q37902663 | ||
| Understanding uveitis: the impact of research on visual outcomes | Q37909585 | ||
| Review and update of intraocular therapy in noninfectious uveitis | Q37928383 | ||
| Difluprednate for inflammatory eye disorders | Q37947609 | ||
| A systematic review of the association of diabetic retinopathy and cognitive impairment in people with Type 2 diabetes | Q37966386 | ||
| Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis | Q38495949 | ||
| SIRT1 activation protects against autoimmune T cell-driven retinal disease in mice via inhibition of IL-2/Stat5 signaling | Q39470105 | ||
| Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis | Q40308355 | ||
| Local cyclosporine therapy for experimental autoimmune uveitis in rats | Q41374533 | ||
| Phase II results of an intraocular steroid delivery system for cataract surgery | Q41671762 | ||
| Adverse events after intravitreal infliximab (Remicade). | Q42642245 | ||
| Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. | Q42869100 | ||
| Combination intravitreal rituximab and methotrexate for massive subretinal lymphoma | Q42938838 | ||
| Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection | Q43071562 | ||
| Intravitreal triamcinolone for intraocular inflammation and associated macular edema | Q43096392 | ||
| Intravitreal adalimumab for refractory uveitis-related macular edema. | Q43105859 | ||
| Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study | Q43122166 | ||
| Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma | Q43147543 | ||
| Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema | Q43225838 | ||
| Mathematical modeling of triamcinolone acetonide drug release from the I-vation intravitreal implant (a controlled release platform). | Q43229029 | ||
| Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies | Q43232467 | ||
| Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial | Q43541201 | ||
| Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab | Q44570349 | ||
| Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease | Q44783874 | ||
| Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period | Q44997164 | ||
| Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis | Q45170976 | ||
| Vitreous concentrations of triamcinolone acetonide in human eyes after intravitreal or subtenon injection | Q45209421 | ||
| Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis | Q45261256 | ||
| Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. | Q45931376 | ||
| Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. | Q45955518 | ||
| Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. | Q45991577 | ||
| Ranibizumab for refractory uveitis-related macular edema. | Q46018981 | ||
| Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema | Q46062208 | ||
| Evaluation of potential retinal toxicity of adalimumab (Humira). | Q46083924 | ||
| Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. | Q46089589 | ||
| Effect of the macromolecular architecture of biodegradable polyurethanes on the controlled delivery of ocular drugs | Q46318162 | ||
| Fingolimod (FTY720) as an acute rescue therapy for intraocular inflammatory disease | Q46318670 | ||
| Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. | Q46403637 | ||
| Effects of intravitreal injection of tacrolimus (FK506) in experimental uveitis | Q46425622 | ||
| Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis--a randomized triple masked study | Q46451266 | ||
| Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis | Q46474975 | ||
| Outcome of intravitreal triamcinolone in uveitis | Q46711026 | ||
| Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study | Q46815448 | ||
| Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. | Q48627948 | ||
| Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. | Q51140243 | ||
| Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. | Q54033436 | ||
| Effect of infliximab on sight-threatening panuveitis in Behçet's disease. | Q54153155 | ||
| Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression | Q57362835 | ||
| Dexamethasone Implant in Pediatric Uveitis | Q57638955 | ||
| Topical application of ciclosporin ophthalmic solution containing alpha-cyclodextrin in experimental uveitis | Q67829506 | ||
| Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis | Q70988225 | ||
| The Effects of Posterior Subtenon Injection of Triamcinolone Acetonide in Patients With Intermediate Uveitis | Q71878418 | ||
| Orbital floor steroid injections in the treatment of uveitis | Q72020579 | ||
| Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement | Q74710765 | ||
| Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema | Q77156632 | ||
| Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group | Q77766048 | ||
| Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma | Q79287102 | ||
| P433 | issue | 1 | |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 39 | |
| P577 | publication date | 2013-08-06 | |
| P1433 | published in | BMC Ophthalmology | Q15765692 |
| P1476 | title | Local therapies for inflammatory eye disease in translation: past, present and future | |
| P478 | volume | 13 |
| Q34793097 | Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation |
| Q37412317 | Birdshot uveitis: current and emerging treatment options |
| Q33849167 | Effects of Mesenchymal Stem Cell-Derived Exosomes on Experimental Autoimmune Uveitis |
| Q48262834 | Green tea extract attenuates LPS-induced retinal inflammation in rats. |
| Q36273801 | In Vitro and In Vivo Sustained Zero-Order Delivery of Rapamycin (Sirolimus) From a Biodegradable Intraocular Device |
| Q104795267 | Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance |
| Q37609648 | Inhibitory effect of a novel peptide, H-RN, on keratitis induced by LPS or poly(I:C) in vitro and in vivo via suppressing NF-κB and MAPK activation |
| Q52338865 | Management of chronic ocular sarcoidosis: challenges and solutions. |
| Q38235720 | Ocular Involvement in Juvenile Idiopathic Arthritis: Classification and Treatment |
| Q92524802 | Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression |
| Q34274075 | Pharmacotherapy for uveitis: current management and emerging therapy |
| Q90403165 | Retinal endothelial cell phenotypic modifications during experimental autoimmune uveitis: a transcriptomic approach |
| Q35873681 | Risk of Retinal Neovascularization in Cases of Uveitis |
| Q91650696 | Safety and efficacy of tacrolimus-coated silicone plates as an alternative to mitomycin C in a rabbit model of conjunctival fibrosis |
| Q38397111 | Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders |
| Q37513981 | Uveitis as a Result of MAP Kinase Pathway Inhibition. |
Search more.